Arcutis Biotherapeutics (ARQT)
(Delayed Data from NSDQ)
$15.33 USD
+0.81 (5.54%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $15.33 +0.01 (0.03%) 5:14 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Dividend Yield (TTM)
Arcutis Biotherapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ARQT 15.33 +0.81(5.54%)
Will ARQT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARQT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARQT
Arcutis Biotherapeutics, Inc. (ARQT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
ARQT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Arcutis Biotherapeutics, Inc. (ARQT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for ARQT
Arcutis Biotherapeutics Inc (ARQT) Q2 2025: Everything You Need to Know Ahead of Earnings
Arcutis: Leveraging Zoryve's Success While Positioning For Pipeline Expansion
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
Carvana upgraded, Ulta Beauty downgraded: Wall Street's top analyst calls
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday